



# AWTTC

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

## **One Wales Medicines Assessment Group (OWMAG)**

### **Minutes of the Teams meeting held Monday 22nd April 2024**

#### Members in attendance

John Watkins, Consultant in Public Health, OWMAG Chair  
Tim Banner, Clinical Director Pharmacy & Medicines Management, representative Cardiff and Vale  
Joe Castle, Operations Manager, ABPI Cymru Wales  
Alan Clatworthy, Clinical Effectiveness and Formulary Pharmacist, representative Swansea Bay  
James Coulson, Clinical Pharmacologist representative.  
Lindsay Davies, Senior Information Pharmacist, representative Cardiff and Vale  
Teena Grenier, Medicines Governance Lead, representative Betsi Cadwaladr  
Will Hardy, Research Fellow, Bangor University, Health Economist  
Kathryn Howard, Head of Pharmacy, Royal Glamorgan Hospital, representative Cwm Taf Morgannwg  
William King, Consultant in Public Health, representative Powys  
Malcolm Latham, Community Health Council, Lay representative  
Hywel Pullen, Assistant Director of Finance, Powys  
Bethan Tranter, Chief Pharmacist, representative AWPAG/Velindre  
Michael Thomas, Consultant in Public Health Medicine, representative Hywel Dda

#### **AWTTC**

Andrew Champion, Programme Director  
Clare Elliott, Senior Appraisal Scientist  
David Haines, Medical Writer  
Stuart Keeping, Senior Appraisal Scientist  
Laura Phillips, Admin Supervisor  
Rosie Spears, Senior Appraisal Scientist  
Gail Woodland, Senior Appraisal Pharmacist  
Tom Winfield, Senior Health Economist

#### **Observers**

#### **List of Abbreviations:**

ABPI	Association of the British Pharmaceutical Industry
AWTTC	All Wales Therapeutics and Toxicology Centre
ESR	Evidence Status Report
IPFR	Individual Patient Funding Request
NICE	National Institute for Health and Care Excellence
NMG	New Medicines Group



# AWTTC

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

OWMAG  
WHSSC

One Wales Medicines Assessment Group  
Welsh Health Specialised Services Committee

## 1. Welcome and Introduction

The Chair opened the meeting and welcomed members.

## 2. Apologies

Ian Campbell, Hospital Consultant CAV, representative NMG

Leo Pinto, Consultant in Public Health, alternative Aneurin Bevan representative

Jonathan Simms, Clinical Director of Pharmacy, representative Aneurin Bevan

## 3. Resignation

Hywel Pullen, Assistant Director of Finance, Powys

## 4. Declarations of Interests/Confidentiality

The Chair reminded members that all OWMAG proceedings are confidential and should not be disclosed outside of the meeting. Members were reminded that declarations of interest and confidentiality statements are signed by each member on an annual basis. The Chair invited any declarations of interest. Hywel Pullen, Assistant Director of Finance, Powys declared that he was also a member of AWMSG. It was noted due to the new process of OWMAG decisions going through AWMSG that Hywel could not sit on both committees. The Chair thanked Hywel for his contribution to the OWMAG committee.

## 5. AWMSG endorsements

Gail Woodland provided feedback from the last AWMSG meeting on the 17<sup>th</sup> April 2024. At AWMSG, the AWMSG Chair announced the 12-month review of the OWMAG decision for abiraterone which will include an update to the starting criteria for abiraterone for the treatment of non-metastatic hormone sensitive prostate cancer to include high risk, relapsing patients. This will now go to Welsh Government for ratification prior to publication.

The AWMSG Chair confirmed AWMSG's endorsement of dabrafenib and trametinib for the treatment of inoperable BRAF V600E variant anaplastic thyroid cancer. This will also now go to Welsh Government for ratification prior to publication.

AWMSG members could not endorse the OWMAG recommendation for the use of nivolumab monotherapy as a first-line treatment for patients with metastatic deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) oesophageal and gastric adenocarcinoma where the programmed death ligand-1 (PD-L1) combined positive score (CPS) is less than 5. The grounds for their non-endorsement were lack of evidence of clinical and cost effectiveness. The AWMSG Chair asked whether additional information could be provided to AWMSG for consideration in



# AWTTC

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

circumstances where the evidence is weak. Following discussion, OWMAG agreed by consensus that a reassessment be undertaken. To support this, AWTTC will strengthen the evidence summary report, taking in to consideration the points raised by AWMSG.

## **6. Infliximab for ICI induced enterocolitis and vedolizumab for ICI induced enterocolitis**

Stuart Keeping presented the proposed approach for the two reviews. The ESMO guidelines have changed and both treatments are now recommended for patients with Grade 2 enterocolitis. In addition, dose escalation of infliximab may now be considered for refractory disease. Clinicians would welcome the option to use vedolizumab for those patients requiring multiple steroid challenges who may benefit from earlier intervention with vedolizumab. The review reports provide evidence for continuation of use consistent with the current One Wales Recommendation for Grade 3 and 4 disease, however assessment to support the extended use in additional patient groups is beyond the scope of the reviews. AWTTC therefore recommend reassessment of the evidence to consider the additional patient groups. It was noted that the current recommendation will stand until the recommendation from the reassessment is ratified by Welsh Government. OWMAG had no queries on this proposal, the vote would be undertaken via email.

## **7. Review process**

David Haines presented an overview of the current process for reviewing One Wales decisions, and some potential changes to the process to members. A questionnaire had been shared with members previously and they were asked to provide opinions and discuss options relating to the review process. The presentation included details of the suggested use of a 'static list' for certain decisions, and gave examples of active decisions that could be moved onto the list. Inclusion criteria for the static list were discussed.

Members were broadly supportive of the static list idea, and it was mentioned that streamlining the review process to allow more time to focus on the quality of the initial decision would be beneficial as this is where the real value of the work is. It was pointed out that the current review process can cause confusion at health board level as staff can mistake an unchanged review for new advice, so limiting the communication if nothing has changed could be helpful.

It was agreed that any medicines on the static list would need to be checked against newly licensed medicines, and that patient outcome data should still be collected. Any significant price changes should also be considered. Members were informed that the internal review process would be retained, so AWTTC would be aware of any significant changes such as this.

Members were also asked about the possibility of removing One Wales decisions entirely if evidence suggested the medicine was no longer being used as per the



# AWTTC

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

decision. It was pointed out that uncertainty around prescribing data could mean that the medicine is still being used, but not reported so any removal of decisions would have to be done very carefully.

Members were thanked for their time, and it was agreed AWTTC will develop a new, draft review process to be brought to a future OWMAG meeting.

The Chair reminded members that the next meeting will be held on Monday 20th May 2024 and this will comprise of an email vote.

The Chair thanked the group and closed the meeting at 11:00.